Last Updated : May 22, 2024
Details
Project Status:
Active
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0082-000
Expected finish date:
Renal cell carcinoma (RCC) is the most common type of kidney cancer and is often diagnosed at a later stage, which makes it difficult to treat. Recent advancements in systemic therapies, such as dual immunotherapy and combinations of immune checkpoint inhibitors with vascular endothelial growth factor (VEGF) inhibitors, have shown promising results. However, real-world data on the use and duration of these treatments is limited.
This study analyzed the use of systemic treatments for advanced RCC in Ontario, Alberta, and British Columbia using population-based data. Among 2,224 patients (mostly males, with an average age of 67), combination therapies like ipilimumab plus nivolumab and axitinib plus pembrolizumab have replaced older drugs and become the dominant first-line treatments. Treatment with first-line therapies lasted 10 to 13 months, while treatment with second-line and third-line options was shorter, at 6 to 8 months.
Last Updated : May 22, 2024